Postos
175I am proud to have reached this milestone.
I would be delighted to receive feedback on my portfolio.
I tend to take a long-term approach, but I find ETFs too boring.🥱 I would like to slim down my portfolio a little and am considering divesting from $LLY (+1,84%) and / or $NOVO B (+1,11%) to divest.
$NOVO B (+1,11%) has been strongly driven by the hype surrounding weight loss injections in recent years, but has also impressed fundamentally with strong EPS growth. After the recent setback, the share price looks attractive again to me.
I see risks above all in the dependence on the US market and the diabetes segment; paradoxically, the company could lose market volume here due to the success of its own products. On the other hand, the potential in the obesity and lifestyle segment remains enormous, and the cash flows enable strong research.
How do you see the current sentiment towards the share, especially in terms of differentiation$LLY (+1,84%) ?
$LLY (+1,84%) announced a $5B investment to build a new manufacturing facility in Virginia.
DOWN -8% AT SOME POINT OF THE DAY
The letter is dated Sep 9.
$HIMS must respond by Sep 30 (within 15 working days).
$HIMS (-0,43%) IS NOT THE ONLY COMPANY THAT RECEIVED WARNING LETTERS FROM THE FDA
$LLY (+1,84%) AND $NOVO B (+1,11%) ALSO RECEIVED LETTERS FOR FALSE & MISLEADING CLAIMS AND MISBRANDED PRODUCTS
$LLY (+1,84%) received three letters -- about Zepbound and Mounjaro.
And $NOVO B (+1,11%) received one letter -- about Wegovy, Ozempic, and Victoza.
The letters target an Oprah primetime special and local TV sponsored segments for omitting key information about $LLY (+1,84%) and $NVO (+1,1%) 's GLP-1s.
The FDA flagged company reps and paid consultants for downplaying pancreatitis and gallbladder risks as "overhyped" and calling thyroid-cancer concerns "very, very rare."
The FDA also flagged the omission of other serious warnings like hypoglycemia, kidney injury, diabetic retinopathy, and suicidal behavior and ideation.
Suffice it to say $HIMS (-0,43%) is not the only company pushing the limits and getting slapped on the wrist. $NVO (+1,1%) and $LLY (+1,84%) have been called out by the FDA as well.
In the end, I actually decided on neither of them.
No industry that appeals to me.
$NOVO B (+1,11%) vs $LLY (+1,84%)
s/o on @Tenbagger2024 in the commis 🫡
$HIMS (-0,43%)
$LLY (+1,84%)
$NOVO B (+1,11%)
Lee Rosebush (Chairman, OFA): "For a year now, we have heard from pharma manufacturers that it was illegal to compound GLP-1 medications. The FDA, through the acknowledgement of the green list, as well as their recent actions on adverse events, has implicitly acknowledged that compounding GLP-1s can occur."
Meanwhile, $LLY (+1,84%) doubling down: "No one should be mass compounding tirzepatide."
Washington Post says U.S. anti-obesity market could reach $68B by 2034, citing Goldman Sachs.
Washington Post also notes (and it really is notable) that $NOVO B (+1,11%) and $LLY (+1,84%) have filed more than 100 lawsuits against compound manufacturers making GLP-1s... and not a single one on intellectual property violations.
Between the FDA's announcement of the Green List and this statement last week:
"FDA has received reports of adverse events associated with compounded versions of semaglutide and tirzepatide ... Many of the adverse events reported for compounded products appear to be consistent with adverse events associated with FDA-approved versions of these products."
"A compounded drug may be appropriate when a patient's medical need cannot be met by an FDA-approved drug or the FDA-approved drug is not commercially available."
While many media outlets and pharmaceutical companies are trying to portray the FDA's announcements as anti-compounding, it appears that the FDA has spoken out on whether this is possible ...
FDA concerns about unapproved GLP-1 weight loss drugs
Understanding unapproved versions of these drugs:
$HIMS (-0,43%)
$LLY (+1,84%)
$NOVO B (+1,11%)
Lee Rosebush (Chairman, OFA): "For a year now, we have heard from pharma manufacturers that it was illegal to compound GLP-1 medications. The FDA, through the acknowledgement of the green list, as well as their recent actions on adverse events, has implicitly acknowledged that compounding GLP-1s can occur."
Meanwhile, $LLY (+1,84%) doubling down: "No one should be mass compounding tirzepatide."
Washington Post says U.S. anti-obesity market could reach $68B by 2034, citing Goldman Sachs.
Washington Post also notes (and it really is notable) that $NOVO B (+1,11%) and $LLY (+1,84%) have filed more than 100 lawsuits against compound manufacturers making GLP-1s... and not a single one on intellectual property violations.
Between the FDA's announcement of the Green List and this statement last week:
"FDA has received reports of adverse events associated with compounded versions of semaglutide and tirzepatide ... Many of the adverse events reported for compounded products appear to be consistent with adverse events associated with FDA-approved versions of these products."
"A compounded drug may be appropriate when a patient's medical need cannot be met by an FDA-approved drug or the FDA-approved drug is not commercially available."
While many media outlets and pharmaceutical companies are trying to portray the FDA's announcements as anti-compounding, it appears that the FDA has spoken out on whether this is possible ...
FDA concerns about unapproved GLP-1 weight loss drugs
Understanding unapproved versions of these drugs:
📈 Performance:
S&P500: +1.51%
MSCI World: +1.76%
DAX: +2.59%
Dividend portfolio: +4.24%
My high and low performers in July were (top/flop 3):
🟢 $UNH (+2,98%) UnitedHealth +16.78%
🟢 $ADM (+1,41%) Archer Daniels Midland +12.33%
🟢 $8058 (+0,07%) Mitsubishi Corp. +12.05%
🔴 $LLY (+1,84%) Eli Lilly -5.99%
🔴 $MSFT (+0,55%) Microsoft -7.51%
🔴 $CTAS (-0,39%) Cintas -9.20%
Dividends:
August 2025: €129.54
August 2024: € 101.41
Change: +27.74% 🥒
Sales:
🟥 $7974 (-0,38%) Nintendo (6 pcs.) +100%
Purchases:
🟩 $PG (+0,3%) Procter & Gamble (4 pcs.)
Savings plans:
What else has happened?
The tax assessment notice has arrived and the back payment has increased to 4100€. Funnily enough (typical for Germany), the advance payment is calculated on the basis of this year. As everything seems to run automatically, nobody checks whether this makes sense. In any case, the tax office assumes that I will have to pay the same amount again next year (or more) and tells me that I should pay €6500 in advance. Of course, I'm now asking for a recalculation. But that's a lot of work again, which could have been avoided if someone had just looked over it. Then they would have seen that this was a one-off. Well, what else do I expect these days.
The appointment at the garage has been arranged for the beginning of September. Let's see what else is in store for me.
I'm going on vacation at the end of September. That will be necessary again. My last vacation was around Christmas last year.
🥅 Goals for 2025:
Deposit of €10,000 and thus a deposit volume in the share portfolio of ~€73,000
Target achievement at the end of August 2025: 60.58%
How was your August?
If you liked the report and would like to read more, feel free to follow me,
If you're not interested, you can keep scrolling or use the block function.
🇺🇸 USA
• $SPX500 — futures held modest gains, continuing upward tone post-Labor Day.
• $DJ30 — futures slightly lower, industrials under gentle pressure.
Tech Snapshot:
•$NVDA (-0,28%) — unchanged over the holiday; AI chip demand remains strong.
• $AVGO (+0,36%) — down ~3.7%, strong AI and hyperscaler demand underpinning medium-term outlook.
• $AMZN (+0,01%) — down ~1.16%; e-commerce and AWS remain growth drivers.
•$META (-1,29%) — down ~1.63%; ads and cloud revenue continue holding up.
• $MSFT (+0,55%) — down ~0.58%; cloud-led momentum supports stability.
•$SHOP (+6,73%) — down ~0.13%; e-commerce resilience offsetting recent volatility.
🇪🇺 Europe
• $EUSTX50 futures — slight dip, cautious sentiment ahead of key data.
• $GER40 futures — mild pullback.
European Banks Spotlight:
• $UCG (+0,1%) — stable; investor confidence in capital returns.
• $ISP (+0,18%) — steady; Q2 fundamentals solid.
• $BPE (-0,19%) — improving profitability trends.
•$BBVA (-0,23%) — consistent execution, stable lending growth.
• $CE (+1,9%) — reliable niche performance.
🌏 Asia
• $JPN225 — mixed; semiconductors underpin performance.
• $KOSPI — modest gains; tech sector support.
• $HK50 — rangebound; cautious China sentiment.
• $CHINA50 — modest movement; cautious positioning.
💳 Payments & Consumer
• $V — up ~0.48%; strong global transaction volumes support growth.
💊 Healthcare & Pharma
•$HIMS (-0,43%) — down ~3.97%; revenue growth remains focus.
•$LLY (+1,84%) — flat (~0.00%); supported by diabetes/obesity treatments.
• $PHIN (+0,41%) — down ~0.65%; sector momentum monitored closely.
💱 Forex
• $EURUSD — euro strengthened against USD.
• $GBPUSD — stable ahead of UK macro data.
• $USDJPY — slightly firmer.
• $DXY — softened marginally.
🥇 Gold (GLD)
• $GLD (+0,55%) — edged higher, supported by softer yields and defensive positioning.
🛢 Oil
• $WTI — held firm.
• $BRENT — held firm.
💰 Crypto
• $BTC (+1,55%) — modest gains; consolidating.
• $ETH (+1,37%) — steady in upper-$4k range.
• $TRX (+0,14%) — minor pullback after recent climb.
• $CRO (-2,38%) — retraced ~5% after breakout; volatility elevated.
Global Insight & Crypto Deep Dive
September begins cautiously: U.S. futures show tentative strength, Europe and Asia rangebound ahead of macro data (ISM, PMI, NFP). Broadcom (~–3.7%) retracement highlights sensitivity to global demand, while Amazon and Meta reflect rotation in tech. Microsoft and Shopify show relative stability.
In crypto, $BTC and $ETH remain steady, providing a base, while $CRO retraces after breakout—watch support levels closely; recovery could reignite momentum, failure could lead to deeper correction.
✨ If you enjoy my daily analysis, make sure to follow me.
$NOVO B (+1,11%) Compared to tirzepatide of $LLY (+1,84%) a 2.4-milligram dose of Wegovy showed a significantly higher risk reduction of 57 percent higher risk reduction for heart attack, stroke and cardiovascular-related death or death from any cause during treatment without gaps of more than 30 days, according to the Danish drug manufacturer.
Data from more than 21,000 patients presented at the European Society of Cardiology meeting in Madrid also showed that the risk of heart disease and death from any cause decreased by 29 percent in Wegovy users compared to tirzepatide users, regardless of any gaps in treatment.
The results could give Novo a boost, as the company has lost market share to Zepbound in the US.
Source: https://de.tradingview.com/news/reuters.com,2025:newsml_L8N3UN05O:0/
Principais criadores desta semana
